Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Completed · Phase 1

Conditions studied: Solid Tumor

In brief

The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.

Key facts

Study ID

NCT02216409

Run by

Gilead Sciences

People needed

88

Starts

2014-08-01

Expected to finish

2018-12-01

Last updated by the study team

2019-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma
• Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.
• Adequate hematologic status
• Adequate coagulation function
• Adequate hepatic function
• Adequate renal function

You may not qualify if…

• Known primary tumors of central nervous system disease
• Known active brain metastases
• Known cardiopulmonary disease

Where it is running

• Stanford Cancer Institute — Stanford, California, United States
• University of Chicago — Chicago, Illinois, United States
• START Midwest — Grand Rapids, Michigan, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• University of Oklahoma — Oklahoma City, Oklahoma, United States
• South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.